{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:01:04Z","timestamp":1782230464662,"version":"3.54.5"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00120-022-01950-0","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T19:02:42Z","timestamp":1666378962000},"page":"41-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Kurzfassung der S2k-Leitlinie medikament\u00f6se Therapie der neurogenen Dysfunktion des unteren Harntraktes (NLUTD)","Short version of the S2k guideline on drug therapy of neurogenic lower urinary tract dysfunction (NLUTD)"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9935-5757","authenticated-orcid":false,"given":"J.","family":"Kutzenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Angermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1309-8911","authenticated-orcid":false,"given":"B.","family":"Domurath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"M\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-7174","authenticated-orcid":false,"given":"J.","family":"Pretzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Soljanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-916X","authenticated-orcid":false,"given":"R.","family":"Kirschner-Hermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"1950_CR1","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/01.ju.0000084623.65480.f8","volume":"170","author":"P Abrams","year":"2003","unstructured":"Abrams\u00a0P, Amarenco\u00a0G, Bakke\u00a0A et\u00a0al (2003) Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J\u00a0Urol 170:1242\u20131251","journal-title":"J Urol"},{"key":"1950_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","volume":"67","author":"P Abrams","year":"2015","unstructured":"Abrams\u00a0P, Kelleher\u00a0C, Staskin\u00a0D et\u00a0al (2015) Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a\u00a0phase 2\u00a0study (symphony). Eur Urol 67:577\u2013588","journal-title":"Eur Urol"},{"key":"1950_CR3","first-page":"13","volume":"6","author":"A Alsulihem","year":"2019","unstructured":"Alsulihem\u00a0A, Corcos\u00a0J (2019) Evaluation, treatment, and surveillance of neurogenic detrusor overactivity in spinal cord injury patients. Neuroimmunol Neuroinflamm 6:13","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"1950_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/nau.22945","volume":"36","author":"G Amarenco","year":"2017","unstructured":"Amarenco\u00a0G, Sutory\u00a0M, Zachoval\u00a0R et al (2017) Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivty: results from the doble-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn 36:414\u2013421","journal-title":"Neurourol Urodyn"},{"key":"1950_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.eururo.2008.01.007","volume":"53","author":"B Amend","year":"2008","unstructured":"Amend\u00a0B, Hennenlotter\u00a0J, Sch\u00e4fer\u00a0T et al (2008) Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 53:1021\u20131028","journal-title":"Eur Urol"},{"key":"1950_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1046\/j.1464-410x.1999.00397.x","volume":"84","author":"KE Andersson","year":"1999","unstructured":"Andersson\u00a0KE, Appell\u00a0RA, Cardozo\u00a0LD et\u00a0al (1999) The pharmacological treatment of urinary incontinence. BJU Int 84:923\u2013947","journal-title":"BJU Int"},{"key":"1950_CR7","first-page":"662","volume-title":"Incontinence","author":"KE Andersson","year":"2012","unstructured":"Andersson\u00a0KE, Chapple\u00a0CR, Cardozo\u00a0L et\u00a0al (2012) Pharmacological treatment of urinary incontinence. In: Abrams\u00a0P, Cardozo\u00a0L, Khoury\u00a0S, Wein\u00a0A (Hrsg) Incontinence 5th International Consultation on Incontinence. EAU\u2014ICUD, Paris, S\u00a0662\u2013663"},{"key":"1950_CR8","first-page":"693","volume-title":"Incontinence","author":"KE Andersson","year":"2012","unstructured":"Andersson\u00a0KE, Chapple\u00a0CR, Cardozo\u00a0L et\u00a0al (2012) Pharmacological treatment of urinary incontinence. In: Abrams\u00a0P, Cardozo\u00a0L, Khoury\u00a0S, Wein\u00a0A (Hrsg) Incontinence 5th Internatinal Consultation on Incontinence. EAU\u2014ICUD, Paris, S\u00a0693"},{"key":"1950_CR9","first-page":"1093","volume-title":"Incontinence","author":"A Apostolidis","year":"2017","unstructured":"Apostolidis\u00a0A, Drake\u00a0MJ, Emmanuel\u00a0A et\u00a0al (2017) Neurologic urinary and feacal incontinence. In: Abrams\u00a0P, Cardozo\u00a0L, Khoury\u00a0S, Wein\u00a0A (Hrsg) Incontinence 6th International Consultation on Incontinence, Tokyo, S\u00a01093\u20131280"},{"key":"1950_CR10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1517\/14656566.2011.554397","volume":"12","author":"A Athanasopoulos","year":"2011","unstructured":"Athanasopoulos\u00a0A (2011) The pharmacotherapy of overactive bladder. Expert Opin Pharmacother 12:1003\u20131005","journal-title":"Expert Opin Pharmacother"},{"key":"1950_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1590\/s1677-5538.ibju.2021.02.03","volume":"47","author":"MA Averbeck","year":"2021","unstructured":"Averbeck\u00a0MA (2021) Editorial comment: long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Int Braz J Urol 47:454\u2013455","journal-title":"Int Braz J Urol"},{"key":"1950_CR12","first-page":"445","volume-title":"Pharmakologische Grundlagen der Arzneimitteltherapie","author":"RJ Baldessarini","year":"1998","unstructured":"Baldessarini\u00a0RJ (1998) Medikamente und die Behandlung psychiatrischer Erkrankungen. In: Dominiak\u00a0P, Harder\u00a0S, Paul\u00a0M, Unger\u00a0T (Hrsg) Pharmakologische Grundlagen der Arzneimitteltherapie. McGraw-Hill, London, New York, S 445\u2013474"},{"key":"1950_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1464-410X.2006.06742.x","volume":"99","author":"MM Barendrecht","year":"2007","unstructured":"Barendrecht\u00a0MM, Oelke\u00a0M, Laguna\u00a0MP et al (2007) Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 99:749\u2013752","journal-title":"BJU Int"},{"key":"1950_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/01.ju.0000103274.38694.b1","volume":"171","author":"N Bennet","year":"2004","unstructured":"Bennet\u00a0N, O\u2019Leary\u00a0M, Patel\u00a0AS et\u00a0al (2004) Can higher doses of oxybutynin improve efficacy in neurogenic bladder. J\u00a0Urol 171:749\u2013751","journal-title":"J Urol"},{"key":"1950_CR15","first-page":"271","volume-title":"Pharmakotherapie in der Urologie","author":"R Berges","year":"2002","unstructured":"Berges\u00a0R (2002) Pharmakologische Therapie von prostatabedingten Miktionsst\u00f6rungen. In: Truss\u00a0MC, Stief\u00a0C, Machtens\u00a0S, Wagner\u00a0T, Jonas\u00a0U (Hrsg) Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg, S\u00a0271\u2013275"},{"key":"1950_CR16","unstructured":"B\u00f6thig R, Domurath B, Bremer J et al (2019) Neuro-urologische Versorgung querschnittgel\u00e4hmter Patienten. S2k-Leitlinie, AWMF-Register Nr: 179\/001. https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/179-001.html. Zugegriffen: 31. Mai 2022"},{"key":"1950_CR17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00120-013-3419-7","volume":"53","author":"R B\u00f6thig","year":"2014","unstructured":"B\u00f6thig\u00a0R, Kaufmann\u00a0A, Bremer\u00a0J et al (2014) Botulinumneurotoxin Typ A bei neurogener Detrusor\u00fcberaktivit\u00e4t Konsensus des Arbeitskreises Neuro-Urologie der DMGP. Urologe 53:524\u2013530","journal-title":"Urologe"},{"key":"1950_CR18","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0022-5347(01)62828-3","volume":"160","author":"G Buyse","year":"1998","unstructured":"Buyse\u00a0G, Waldeck\u00a0K, Verpoorten\u00a0C et\u00a0al (1998) Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J\u00a0Urol 160:892\u2013896","journal-title":"J Urol"},{"key":"1950_CR19","first-page":"A190","volume":"22","author":"J Bycroft","year":"2003","unstructured":"Bycroft\u00a0J, Leaker\u00a0B, Wood\u00a0S et\u00a0al (2003) The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. Neurourol Urodyn 22:A190","journal-title":"Neurourol Urodyn"},{"key":"1950_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","volume":"72","author":"E Callegari","year":"2011","unstructured":"Callegari\u00a0E, Malhotra\u00a0B, Bungay\u00a0PJ et al (2011) A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72:235\u2013246","journal-title":"Br J Clin Pharmacol"},{"key":"1950_CR21","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.juro.2009.05.038","volume":"182","author":"AP Cameron","year":"2009","unstructured":"Cameron\u00a0AP, Clemens\u00a0JQ, Latini\u00a0JM et\u00a0al (2009) Combination drug therapy improves compliance of the neurogenic bladder. J\u00a0Urol 182:1062\u20131067","journal-title":"J Urol"},{"key":"1950_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","volume":"18","author":"M Chancellor","year":"2012","unstructured":"Chancellor\u00a0M, Boone\u00a0T (2012) Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 18:167\u2013174","journal-title":"CNS Neurosci Ther"},{"key":"1950_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0090-4295(02)01803-4","volume":"60","author":"CR Chapple","year":"2002","unstructured":"Chapple\u00a0CR, Yamanishi\u00a0T, Chess-Williams\u00a0R (2002) Muscarinic receptor subtypes and mangement of the overactive bladder. Urology 60:82\u201388","journal-title":"Urology"},{"key":"1950_CR24","doi-asserted-by":"publisher","first-page":"744","DOI":"10.2340\/16501977-0255","volume":"40","author":"SL Chen","year":"2008","unstructured":"Chen\u00a0SL, Bih\u00a0LI, Huang\u00a0YH et\u00a0al (2008) Effect of single Botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury. J\u00a0Rehabil Med 40:744\u2013748","journal-title":"J Rehabil Med"},{"key":"1950_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.12965\/jer.1632874.437","volume":"12","author":"YS Cho","year":"2016","unstructured":"Cho\u00a0YS, Kim\u00a0KH (2016) Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity. J\u00a0Exerc Rehabil 12:624\u2013631","journal-title":"J Exerc Rehabil"},{"key":"1950_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000102915","volume":"79","author":"F Christoph","year":"2007","unstructured":"Christoph\u00a0F, Moschkowitsch\u00a0A, Kempkensteffen\u00a0C et al (2007) Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity. Urol Int 79:55\u201359","journal-title":"Urol Int"},{"key":"1950_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000241674","volume":"83","author":"E Constantini","year":"2009","unstructured":"Constantini\u00a0E, Lazzeri\u00a0M, Bini\u00a0V et al (2009) Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urol Int 83:311\u2013315","journal-title":"Urol Int"},{"key":"1950_CR28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz\u00a0F, Herschorn\u00a0S, Aliotta\u00a0P et al (2011) Efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60:742\u2013750","journal-title":"Eur Urol"},{"key":"1950_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/acprof:oso\/9780195306637.003.0019","volume-title":"Central regulation of autonomic functions","author":"WC De Groat","year":"2011","unstructured":"De Groat\u00a0WC (2011) Autonomic regulation of the urinary bladder and urethra. In: Llewellyn-Smith\u00a0IJ, Ververne\u00a0AJM (Hrsg) Central regulation of autonomic functions. Oxford University, Oxford, S 345\u2013365"},{"key":"1950_CR30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1146\/annurev.pharmtox.41.1.691","volume":"41","author":"WC De Groat","year":"2001","unstructured":"De Groat\u00a0WC, Yoshimura\u00a0N (2001) Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 41:691\u2013721","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1950_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0302-2838(02)00209-9","volume":"42","author":"M De S\u00e8ze","year":"2002","unstructured":"De S\u00e8ze\u00a0M, Petit\u00a0H, Gallien\u00a0P et al (2002) Botulinum A toxine and detrusor sphincter dyssyergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42:56\u201362","journal-title":"Eur Urol"},{"key":"1950_CR32","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1097\/01.ju.0000049903.60057.4b","volume":"169","author":"S De Wachter","year":"2003","unstructured":"De Wachter\u00a0S, Wyndaele\u00a0JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder afferents. J\u00a0Urol 169:1892\u20131895","journal-title":"J Urol"},{"key":"1950_CR33","unstructured":"Deutsche Gesellschaft f\u00fcr Geriatrie (2022) Was ist Geriatrie? https:\/\/www.dggeriatrie.de. Zugegriffen: 15. Aug. 2022"},{"key":"1950_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-011-2644-1","author":"B Domurath","year":"2011","unstructured":"Domurath\u00a0B, Kutzenberger\u00a0J (2011) Langzeitergebnisse der Anwendung von Botulinumneurotoxin (BoNT) zur Behandlung einer neurogenen OAB bei querschnittgel\u00e4hmten Patienten. Abstracts des 63. Kongresses der DGU. Urologie. https:\/\/doi.org\/10.1007\/s00120-011-2644-1","journal-title":"Urologie"},{"key":"1950_CR35","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","volume":"44","author":"O Doroshyenko","year":"2005","unstructured":"Doroshyenko\u00a0O, Jetter\u00a0A, Odenthal\u00a0KP et\u00a0al (2005) Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 44:701\u2013720","journal-title":"Clin Pharmacokinet"},{"key":"1950_CR36","first-page":"1121","volume-title":"Incontinence","author":"MJ Drake","year":"2017","unstructured":"Drake\u00a0MJ, Apostolidis\u00a0A, Emmanuel\u00a0A et\u00a0al (2017) Neurologic urinary and feacal incontinence. In: Abrams\u00a0P, Cardozo\u00a0L, Khoury\u00a0S, Wein\u00a0A (Hrsg) Incontinence 6th International Consultation on Incontinence, Tokyo, S\u00a01121\u20131128"},{"key":"1950_CR37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","volume":"70","author":"MJ Drake","year":"2016","unstructured":"Drake\u00a0MJ, Chapple\u00a0C, Esen\u00a0AA et al (2016) Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4\u2011week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 70:136\u2013145","journal-title":"Eur Urol"},{"key":"1950_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/bju.13945","volume":"120","author":"MJ Drake","year":"2017","unstructured":"Drake\u00a0MJ, Nitti\u00a0VW, Ginsberg\u00a0D et al (2017) Comparative assessment of the efficacy of onabotulinumtoxin A and oral therapies (anticholinergics and mirabegron) for overactive bladder: a\u00a0systematic review and network meta-analysis. BJU Int 120:611\u2013622","journal-title":"BJU Int"},{"key":"1950_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s001929970003","volume":"10","author":"HP Drutz","year":"1999","unstructured":"Drutz\u00a0HP, Appell\u00a0RA, Gleason\u00a0D et\u00a0al (1999) Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol\u00a0J 10:283\u2013289","journal-title":"Int Urogynecol J"},{"key":"1950_CR40","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","volume":"139","author":"DD Dykstra","year":"1988","unstructured":"Dykstra\u00a0DD, Sidi\u00a0AA, Scott\u00a0AB et al (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J\u00a0Urol 139:919\u2013922","journal-title":"J Urol"},{"key":"1950_CR41","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1097\/01.ju.0000176622.81796.89","volume":"174","author":"PI Ellsworth","year":"2005","unstructured":"Ellsworth\u00a0PI, Borgstein\u00a0NG, Nijman\u00a0RJM et\u00a0al (2005) Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. J\u00a0Urol 174:1647\u20131651","journal-title":"J Urol"},{"key":"1950_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/10790268.2004.11753751","volume":"27","author":"KD Ethans","year":"2004","unstructured":"Ethans\u00a0KD, Nance\u00a0PW, Bard\u00a0RJ et\u00a0al (2004) Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J\u00a0Spinal Cord Med 27:214\u2013218","journal-title":"J Spinal Cord Med"},{"key":"1950_CR43","volume-title":"Zusammenfassung der Merkmale des Arzneimittels \u2013 Emselex","author":"European Medical Agency","year":"2009","unstructured":"European Medical Agency (2009) Zusammenfassung der Merkmale des Arzneimittels \u2013 Emselex"},{"key":"1950_CR44","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00120-009-2208-9","volume":"49","author":"C Frohme","year":"2010","unstructured":"Frohme\u00a0C, Varga\u00a0Z, Olbert\u00a0P et al (2010) Wirkung von Botulinumtoxin A in der ein- und mehrmaligen Behandlung der \u00fcberaktiven Blase. Eine prospektive Analyse. Urologe 49:639\u2013644","journal-title":"Urologe"},{"key":"1950_CR45","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/dmd.109.027144","volume":"37","author":"J Geyer","year":"2009","unstructured":"Geyer\u00a0J, Gavrilova\u00a0O, Petzinger\u00a0E (2009) The role of P\u2011glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 37:1371\u20131374","journal-title":"Drug Metab Dispos"},{"key":"1950_CR46","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0022-5347(17)49941-1","volume":"132","author":"I Gilja","year":"1984","unstructured":"Gilja\u00a0I, Radej\u00a0M, Kovacic\u00a0M et\u00a0al (1984) Conservative treatment of female stress incontinence with imipramine. J\u00a0Urol 132:909\u2013911","journal-title":"J Urol"},{"key":"1950_CR47","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg\u00a0D, Gousse\u00a0A, Keppenne\u00a0V et\u00a0al (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J\u00a0Urol 187:2131\u20132139","journal-title":"J Urol"},{"key":"1950_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00120-007-1326-5","volume":"46","author":"M Goepel","year":"2007","unstructured":"Goepel\u00a0M, Steinwachs\u00a0KC (2007) Wie beeinflussen Medikamente zur Therapie der Harninkontinenz die Gehirnfunktion beim \u00e4lteren Menschen? Urologe 46:387\u2013392","journal-title":"Urologe"},{"key":"1950_CR49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1586\/ern.12.61","volume":"12","author":"ASOM Goessaert","year":"2012","unstructured":"Goessaert\u00a0ASOM, Everaert\u00a0KCMM (2012) Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury and multiple sclerosis. Expert Rev Neurother 12:763\u2013775","journal-title":"Expert Rev Neurother"},{"key":"1950_CR50","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0090-4295(99)00477-X","volume":"55","author":"C Goessl","year":"2000","unstructured":"Goessl\u00a0C, Sauter\u00a0T, Michael\u00a0T et\u00a0al (2000) Efficacy and tolerability of tolterodine in children with detrusor hperreflexia. Urology 55:414\u2013418","journal-title":"Urology"},{"key":"1950_CR51","first-page":"18","volume-title":"Urodynamik","author":"C Hampel","year":"2012","unstructured":"Hampel\u00a0C, Th\u00fcroff\u00a0JW (2012) Pharmakologie des Harntraktes. In: Schultz-Lampel\u00a0D, Goepel\u00a0M, Haferkamp\u00a0A (Hrsg) Urodynamik. Springer, Berlin, Heidelberg, S 18\u201336"},{"key":"1950_CR52","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41393-019-0411-0","volume":"58","author":"KP Hebert","year":"2020","unstructured":"Hebert\u00a0KP, Klarskov\u00a0P, Bagi\u00a0P et\u00a0al (2020) Long term continuation with repeated botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. Spinal Cord 58:675\u2013681","journal-title":"Spinal Cord"},{"key":"1950_CR53","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/nau.20289","volume":"25","author":"M Horstmann","year":"2006","unstructured":"Horstmann\u00a0M, Schaefer\u00a0T, Aguilar\u00a0Y et\u00a0al (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25:441\u2013445","journal-title":"Neurourol Urodyn"},{"key":"1950_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s002400100175","volume":"29","author":"JM Hunsballe","year":"2001","unstructured":"Hunsballe\u00a0JM, Djurhuus\u00a0JC (2001) Clinical options for imipramine in the management of urinary incontinence. Urol Res 29:118\u2013125","journal-title":"Urol Res"},{"key":"1950_CR55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2151458517696680","volume":"8","author":"T Ikpeze","year":"2017","unstructured":"Ikpeze\u00a0T, Mesfin\u00a0A (2017) Spinal cord injury in the geriatric population: risk factors, treatment options, and long-term management. Geriatr Orthop Surg Rehabil 8:115\u2013118","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"1950_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00702-012-0914-8","volume":"120","author":"WH Jost","year":"2013","unstructured":"Jost\u00a0WH (2013) Urological problems in Parkinson\u2019s disease: clinical aspects. J\u00a0Neural Transm 120:587\u2013591","journal-title":"J Neural Transm"},{"key":"1950_CR57","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/00005392-199907000-00069","volume":"162","author":"SY Jung","year":"1999","unstructured":"Jung\u00a0SY, Fraser\u00a0MO, Ozawa\u00a0H et\u00a0al (1999) Urethral afferent nerve activity affects the micturition reflex: implication for the relationship between stress incontinence and detrusor instability. J\u00a0Urol 162:204\u2013212","journal-title":"J Urol"},{"key":"1950_CR58","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/iju.14319","volume":"27","author":"K Kaga","year":"2020","unstructured":"Kaga\u00a0K, Yamanishi\u00a0T, Kaga\u00a0M et\u00a0al (2020) Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and\/or low compliance bladder. Int J Urol 27:899\u2013904","journal-title":"Int J Urol"},{"key":"1950_CR59","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","volume":"50","author":"G Kay","year":"2006","unstructured":"Kay\u00a0G, Crook\u00a0T, Rekeda\u00a0L et\u00a0al (2006) Differential effects of the antimuscarinc agents darifenacin and oxybutynin ER in memory in older subjects. Eur Urol 50:317\u2013326","journal-title":"Eur Urol"},{"key":"1950_CR60","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/j.1742-1241.2008.01849.x","volume":"62","author":"GG Kay","year":"2008","unstructured":"Kay\u00a0GG, Ebinger\u00a0U (2008) Preserving cognitive function for patients with overactive bladder: evidence for a\u00a0differential effect with darifenacin. Int J Clin Pract 62:1792\u20131800","journal-title":"Int J Clin Pract"},{"key":"1950_CR61","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher\u00a0C, Hakimi\u00a0Z, Zur\u00a0R et al (2018) Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol 74:324\u2013333","journal-title":"Eur Urol"},{"key":"1950_CR62","first-page":"182","volume":"10","author":"MJ Kennelly","year":"2008","unstructured":"Kennelly\u00a0MJ, Devoe\u00a0WB (2008) Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol 10:182\u2013191","journal-title":"Rev Urol"},{"key":"1950_CR63","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/978-3-642-67146-3_7","volume-title":"Urologie bei R\u00fcckenmarkverletzten","author":"H Kieswetter","year":"1979","unstructured":"Kieswetter\u00a0H (1979) Medikament\u00f6se Behandlung. In: Urologie bei R\u00fcckenmarkverletzten. Springer, Berlin, Heidelberg, S\u00a054\u201371"},{"key":"1950_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5213\/inj.2040082.041","volume":"24","author":"YJ Kim","year":"2020","unstructured":"Kim\u00a0YJ, Tae\u00a0BS, Bae\u00a0JH (2020) Cognitive function and urologic medications for lower urinary tract symptoms. Int Neurourol\u00a0J 24:231\u2013240","journal-title":"Int Neurourol J"},{"key":"1950_CR65","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.urology.2004.11.021","volume":"65","author":"YT Kim","year":"2005","unstructured":"Kim\u00a0YT, Yoshimura\u00a0N, Masuda\u00a0H et al (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65:238\u2013242","journal-title":"Urology"},{"key":"1950_CR66","series-title":"ICS Online","volume-title":"Efficacy of fesoterodine fumurate in neurogenic detrusor overactivity due to spinal cord lesions and multiple sclerosis (MS)\u2014a\u00a0prospective study","author":"C Konstantinidis","year":"2020","unstructured":"Konstantinidis\u00a0C, Samarinas\u00a0M, Kratiras\u00a0Z et\u00a0al (2020) Efficacy of fesoterodine fumurate in neurogenic detrusor overactivity due to spinal cord lesions and multiple sclerosis (MS)\u2014a\u00a0prospective study. ICS Online"},{"key":"1950_CR67","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000363658","volume":"93","author":"K Kosilov","year":"2014","unstructured":"Kosilov\u00a0K, Loparev\u00a0SA, Ivanovaskaya\u00a0MA et al (2014) Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate averactive bladder symptoms in elderly men and women. Urol Int 93:470\u2013473","journal-title":"Urol Int"},{"key":"1950_CR68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00345-011-0803-z","volume":"31","author":"J Kranz","year":"2013","unstructured":"Kranz\u00a0J, Petzinger\u00a0E, Geyer\u00a0J (2013) Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World J Urol 31:219\u2013224","journal-title":"World J Urol"},{"key":"1950_CR69","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/sc.2012.164","volume":"51","author":"J Krebs","year":"2013","unstructured":"Krebs\u00a0J, Pannek\u00a0J (2013) Effects of solifenacin in patients with neurogenic detrusor overactivity as a\u00a0result of spinal cord injury. Spinal Cord 51:306\u2013309","journal-title":"Spinal Cord"},{"key":"1950_CR70","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/nau.23566","volume":"37","author":"J Krhut","year":"2018","unstructured":"Krhut\u00a0J, Borovicka\u00a0V, B\u00edlkov\u00e1\u00a0K (2018) Efficacy and safety of mirabegron for the tratment of neurogenic detrusor overactivity\u2014prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 37:2226\u20132233","journal-title":"Neurourol Urodyn"},{"key":"1950_CR71","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40272-017-0249-x","volume":"19","author":"P Kroll","year":"2017","unstructured":"Kroll\u00a0P (2017) Pharmacotherapy for pediatric neurogenic bladder. Pediatr Drugs 19:463\u2013478","journal-title":"Pediatr Drugs"},{"key":"1950_CR72","unstructured":"Kutzenberger J, Angermund A, Domurath B et al (2022) Medikament\u00f6se Therapie der neurogenen Dysfunktion des unteren Harntraltes (NLUTD) S2k Leitlinie AWMF-Register-Nr.\u00a0043-053. https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/043-053.html. Zugegriffen: 30. Juni 2022"},{"key":"1950_CR73","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.eururo.2016.03.052","volume":"70","author":"L Leitner","year":"2016","unstructured":"Leitner\u00a0L, Guggenb\u00fchl-Roy\u00a0S, Kn\u00fcpfer\u00a0SC et al (2016) More than 15\u00a0years of experience with intradetrusor onabotulinumtoxin A injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. Eur Urol 70:522\u2013528","journal-title":"Eur Urol"},{"key":"1950_CR74","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0022-5347(17)55307-0","volume":"124","author":"JFJ Leyson","year":"1980","unstructured":"Leyson\u00a0JFJ, Martin\u00a0BF, Sporer\u00a0A (1980) Baclofen in the treatment of detrusor sphincter dyssynergia in spinal cord injury patients. J\u00a0Urol 124:82\u201384","journal-title":"J Urol"},{"key":"1950_CR75","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1471-0528.1999.tb08119.x","volume":"106","author":"HH Lin","year":"1999","unstructured":"Lin\u00a0HH, Sheu\u00a0BC, Lo\u00a0MC et\u00a0al (1999) Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynecol 106:1089\u20131092","journal-title":"Br J Obstet Gynecol"},{"key":"1950_CR76","first-page":"217","volume":"28","author":"H Madersbacher","year":"1990","unstructured":"Madersbacher\u00a0H (1990) The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia 28:217\u2013229","journal-title":"Paraplegia"},{"key":"1950_CR77","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/sc.2013.19","volume":"51","author":"H Madersbacher","year":"2013","unstructured":"Madersbacher\u00a0H, M\u00fcrtz\u00a0G, St\u00f6hrer\u00a0M (2013) Neurogenic detrusor overactivity in adults: a review on efficacy, tolerabilty and safety of oral antimuscarinics. Spinal Cord 51:432\u2013441","journal-title":"Spinal Cord"},{"key":"1950_CR78","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","volume":"75","author":"H Madersbacher","year":"1995","unstructured":"Madersbacher\u00a0H, St\u00f6hrer\u00a0M, Richter\u00a0R et al (1995) Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 75:452\u2013456","journal-title":"Br J Urol"},{"key":"1950_CR79","first-page":"CD005429","volume":"1","author":"P Madhuvrata","year":"2012","unstructured":"Madhuvrata\u00a0P, Cody\u00a0JD, Ellis\u00a0G et\u00a0al (2012) Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 1:CD5429","journal-title":"Cochrane Database Syst Rev"},{"key":"1950_CR80","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","volume":"62","author":"P Madhuvrata","year":"2012","unstructured":"Madhuvrata\u00a0P, Singh\u00a0M, Hasafa\u00a0Z et al (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 62:816\u2013830","journal-title":"Eur Urol"},{"key":"1950_CR81","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jpurol.2012.02.008","volume":"8","author":"B Malhotra","year":"2012","unstructured":"Malhotra\u00a0B, El-Tahtawy\u00a0A, Wang\u00a0EQ et al (2012) Dose-escalating study of the pharmacokinetics and tolerability of fesoterodin in children with overactive bladder. J\u00a0Pediatr Urol 8:336\u2013342","journal-title":"J Pediatr Urol"},{"key":"1950_CR82","first-page":"343","volume":"57","author":"B Medhi","year":"2013","unstructured":"Medhi\u00a0B, Mittal\u00a0N, Bansal\u00a0D et al (2013) Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding\/over active bladder: a systemativ review. Indian J Physiol Pharmacol 57:343\u2013353","journal-title":"Indian J Physiol Pharmacol"},{"key":"1950_CR83","doi-asserted-by":"publisher","first-page":"623","DOI":"10.5414\/CPP44623","volume":"44","author":"M Menarini","year":"2006","unstructured":"Menarini\u00a0M, Del Popolo\u00a0G, Di Benedetto\u00a0P et\u00a0al (2006) Trospium chloride in patients with neurogenic detrusor overactivty: Is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 44:623\u2013632","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1950_CR84","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/luts.12044","volume":"7","author":"KH Moon","year":"2015","unstructured":"Moon\u00a0KH, Park\u00a0CH, Jung\u00a0HC et al (2015) A 12-week, open label, multi-center study to evaluate the clinical efficacy and safety of silodosin on voiding dysfunction in patients with neurogenic bladder. Low Urin Tract Symptoms 7:27\u201331","journal-title":"Low Urin Tract Symptoms"},{"key":"1950_CR85","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14740338.2019.1652269","volume":"18","author":"AE Muderrisoglu","year":"2019","unstructured":"Muderrisoglu\u00a0AE, Becher\u00a0KF, Madersbacher\u00a0S et\u00a0al (2019) Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf 18:915\u2013923","journal-title":"Expert Opin Drug Saf"},{"key":"1950_CR86","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000072681","volume":"71","author":"S Murakami","year":"2003","unstructured":"Murakami\u00a0S, Yoshida\u00a0M, Iwashita\u00a0H et al (2003) Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int 71:290\u2013298","journal-title":"Urol Int"},{"key":"1950_CR87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-5347(17)38673-1","volume":"142","author":"JB Nanninga","year":"1989","unstructured":"Nanninga\u00a0JB, Frost\u00a0F, Penn\u00a0R (1989) Effect of intrathecal baclofen on bladder and sphincter function. J\u00a0Urol 142:101\u2013105","journal-title":"J Urol"},{"key":"1950_CR88","unstructured":"NCT (2022) A study to find out how fesoterodine works in children aged 6 to 17\u00a0years with bladder overactivity caused by a\u00a0neurological condition. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01557244. Zugegriffen: 30. Juli 2022"},{"key":"1950_CR89","first-page":"1010","volume-title":"Incontinence","author":"R Nijman","year":"2017","unstructured":"Nijman\u00a0R, Tekgul\u00a0S, Chase\u00a0J et\u00a0al (2017) Diagnosis and management of urinary incontience in childhood. In: Abrams\u00a0P, Cardozo\u00a0L, Wagg\u00a0A, Wein\u00a0A (Hrsg) Incontinence 6th International Consultation on Incontinence, Tokyo, S\u00a01010\u20131016"},{"key":"1950_CR90","first-page":"1129","volume":"60","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant\u00a0L, Hall\u00e9n\u00a0B, Larsson\u00a0G (1997) Tolterodine\u2014a\u00a0new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Proc Natl Sci Counc Repub China\u00a0B 60:1129\u20131136","journal-title":"Proc Natl Sci Counc Repub China B"},{"key":"1950_CR91","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/10790268.2003.11753678","volume":"26","author":"M O\u2019Leary","year":"2003","unstructured":"O\u2019Leary\u00a0M, Erickson\u00a0JR, Smith\u00a0CP et al (2003) Effect of controlled-relase oxybutynin on neurogenic bladder function in spinal cord injury. J\u00a0Spinal Cord Med 26:159\u2013162","journal-title":"J Spinal Cord Med"},{"key":"1950_CR92","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/ageing\/afv077","volume":"44","author":"M Oelke","year":"2015","unstructured":"Oelke\u00a0M, Becher\u00a0K, Castro-Diaz\u00a0D et al (2015) Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a\u00a0systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 44:745\u2013755","journal-title":"Age Ageing"},{"key":"1950_CR93","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sc.2008.165","volume":"47","author":"J Pannek","year":"2009","unstructured":"Pannek\u00a0J, Janek\u00a0S, Sommerer\u00a0F et al (2009) Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a\u00a0preliminary immunohistochemical study. Spinal Cord 47:561\u2013564","journal-title":"Spinal Cord"},{"key":"1950_CR94","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/sj.sc.3100517","volume":"36","author":"H Petit","year":"1998","unstructured":"Petit\u00a0H, Wiart\u00a0L, Gaujard\u00a0E et al (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36:91\u201394","journal-title":"Spinal Cord"},{"key":"1950_CR95","first-page":"32","volume":"112","author":"H Petri","year":"2015","unstructured":"Petri\u00a0H (2015) Das Interaktionspotential der urologischen Spasmolytika. CYP450-Wechselwirkungen. Dtsch Arztebl 112:32","journal-title":"Dtsch Arztebl"},{"key":"1950_CR96","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/nau.23009","volume":"36","author":"B Peyronnet","year":"2017","unstructured":"Peyronnet\u00a0B, Castel-Lacanal\u00a0E, Roumiguie\u00a0M (2017) Intradetrusor injections of onabotulinum toxin A (Botox\u00ae) 300\u202fU or 200\u202fU versus abobotulinum toxin A (Dysport\u00ae) 750\u202fU in the management of neurogenic detrusor overactivity: a case control study. Neurourol Urodyn 36:734\u2013739","journal-title":"Neurourol Urodyn"},{"key":"1950_CR97","series-title":"Abstractband","first-page":"15","volume-title":"Ist die Effektivit\u00e4t der intravesikalen Injektion von Botox\u00ae bei querschnittgel\u00e4hmten Patienten eine Dosisfrage? Ein Vergleich von 200\u202fAE, 300\u202fAE und 400\u202fAE","author":"V Polishchuk","year":"2015","unstructured":"Polishchuk\u00a0V, Domurath\u00a0B (2015) Ist die Effektivit\u00e4t der intravesikalen Injektion von Botox\u00ae bei querschnittgel\u00e4hmten Patienten eine Dosisfrage? Ein Vergleich von 200\u202fAE, 300\u202fAE und 400\u202fAE. 28. Jahretagung DMGP, Kassel. Abstractband, S\u00a015"},{"key":"1950_CR98","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jpurol.2008.05.003","volume":"4","author":"PP Reddy","year":"2008","unstructured":"Reddy\u00a0PP, Borgstein\u00a0NG, Nijman\u00a0RJM et al (2008) Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J\u00a0Pediatr Urol 4:428\u2013433","journal-title":"J Pediatr Urol"},{"key":"1950_CR99","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0022-5347(17)35930-X","volume":"150","author":"DA Rivas","year":"1993","unstructured":"Rivas\u00a0DA, Chancellor\u00a0MB, Hill\u00a0K et\u00a0al (1993) Neurological manifestations of baclofen withdrawal. J\u00a0Urol 150:1903\u20131905","journal-title":"J Urol"},{"key":"1950_CR100","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1001\/jama.1976.03270190045029","volume":"236","author":"DS Robinson","year":"1976","unstructured":"Robinson\u00a0DS, Barker\u00a0E (1976) Tricyclic antidepressant cardiotoxicity. JAMA 236:2089\u20132090","journal-title":"JAMA"},{"key":"1950_CR101","first-page":"318","volume":"24","author":"CW Roy","year":"1986","unstructured":"Roy\u00a0CW, Wakefield\u00a0IR (1986) Baclofen pseudopsychosis: case report. Paraplegia 24:318\u2013321","journal-title":"Paraplegia"},{"key":"1950_CR102","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/nau.24039","volume":"38","author":"MP Schneider","year":"2019","unstructured":"Schneider\u00a0MP, Tornic\u00a0J, Sykora\u00a0R et al (2019) Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. A report from the Neuro-Urology Promotion Comittee of the International Continence Society (ICS). Neurourol Urodyn 38:1482\u20131491","journal-title":"Neurourol Urodyn"},{"key":"1950_CR103","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/nau.22755","volume":"35","author":"A Schr\u00f6der","year":"2016","unstructured":"Schr\u00f6der\u00a0A, Albrecht\u00a0U, Schnitker\u00a0J et al (2016) Efficacy, safety, and tolerability of intravesically administered 0.1\u202f% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial. Neurourol Urodyn 35:582\u2013588","journal-title":"Neurourol Urodyn"},{"key":"1950_CR104","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/a-0599-0697","volume":"87","author":"H Schulte-Baukloh","year":"2019","unstructured":"Schulte-Baukloh\u00a0H, Bauer\u00a0R, Jost\u00a0W et al (2019) Botulinumtoxin bei Blasenfunktionsst\u00f6rungen. Fortschr Neurol Psychiatr 87:23\u201330","journal-title":"Fortschr Neurol Psychiatr"},{"key":"1950_CR105","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0022-5347(01)66376-6","volume":"155","author":"B Schurch","year":"1996","unstructured":"Schurch\u00a0B, Hauri\u00a0D, Rodic\u00a0B et al (1996) Botulinum\u2014a toxin as a\u00a0treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J\u00a0Urol 155:1023\u20131029","journal-title":"J Urol"},{"key":"1950_CR106","first-page":"84","volume":"17","author":"IK Singh","year":"2014","unstructured":"Singh\u00a0IK, Bajpaj\u00a0M (2014) A clinical and urodynamic study on the effects of oral tolterodine on serial alterations in neurogenic detrusor overactivity vis-\u00e0-vis oral oxybutynin in children (existing oxybutynin users). J\u00a0Progr Paediatr Urol 17:84\u201388","journal-title":"J Progr Paediatr Urol"},{"key":"1950_CR107","first-page":"1","volume":"16","author":"MA Soebadi","year":"2019","unstructured":"Soebadi\u00a0MA, Hakim\u00a0L, Van Der Aa\u00a0F et al (2019) Real-life data on mirabegron in neurogenic bladder dysfunction. Urol Int 16:1\u20137","journal-title":"Urol Int"},{"key":"1950_CR108","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/j.1742-1241.2010.02433.x","volume":"64","author":"D Staskin","year":"2010","unstructured":"Staskin\u00a0D, Kay\u00a0G, Tannenbaum\u00a0C et\u00a0al (2010) Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64:1294\u20131300","journal-title":"Int J Clin Pract"},{"key":"1950_CR109","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1532-5415.2010.02988.x","volume":"58","author":"D Staskin","year":"2010","unstructured":"Staskin\u00a0D, Kay\u00a0G, Tannenbaum\u00a0C et\u00a0al (2010) Trospium chloride is undetectable in the older human central nervous system. J\u00a0Am Geriatr Soc 58:1618\u20131619","journal-title":"J Am Geriatr Soc"},{"key":"1950_CR110","unstructured":"Statistisches Bundesamt (2022) Bev\u00f6lkerung \u2013 \u00c4ltere Menschen \u2013 Die Bev\u00f6lkerungsgruppe der \u00e4lteren Menschen ab 65\u00a0Jahren. http:\/\/www.destatis.de. Zugegriffen: 30. Juli 2022"},{"key":"1950_CR111","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/nau.24211","volume":"39","author":"R Stein","year":"2020","unstructured":"Stein\u00a0R, Bogaert\u00a0G, Dogan\u00a0HS et\u00a0al (2020) EAU\/ESPU guidelines on the mangement of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. Neurourol Urodyn 39:45\u201357","journal-title":"Neurourol Urodyn"},{"key":"1950_CR112","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.sc.3100750","volume":"37","author":"M St\u00f6hrer","year":"1999","unstructured":"St\u00f6hrer\u00a0M, Madersbacher\u00a0H, Richter\u00a0R et al (1999) Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia\u2014a double-blind, placebo-controlled clinical trial. Spinal Cord 37:196\u2013200","journal-title":"Spinal Cord"},{"key":"1950_CR113","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/sc.2012.174","volume":"51","author":"M St\u00f6hrer","year":"2013","unstructured":"St\u00f6hrer\u00a0M, M\u00fcrtz\u00a0G, Kramer\u00a0G (2013) Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity. Spinal Cord 51:419\u2013423","journal-title":"Spinal Cord"},{"key":"1950_CR114","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.eururo.2006.03.016","volume":"51","author":"M St\u00f6hrer","year":"2007","unstructured":"St\u00f6hrer\u00a0M, M\u00fcrtz\u00a0G, Kramer\u00a0G et al (2007) Propiverine compared to oxybutynin in neurogenic detrusor overactivity\u2014results of a\u00a0randomized, double-blind, multicenter clinical study. Eur Urol 51:235\u2013242","journal-title":"Eur Urol"},{"key":"1950_CR115","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/sc.2016.63","volume":"54","author":"L Stothers","year":"2016","unstructured":"Stothers\u00a0L, Tsang\u00a0B, Nigro\u00a0M et\u00a0al (2016) An integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction. Spinal Cord 54:1114\u20131120","journal-title":"Spinal Cord"},{"key":"1950_CR116","first-page":"420","volume":"28","author":"A Talalla","year":"1990","unstructured":"Talalla\u00a0A, Grundy\u00a0D, Macdonell\u00a0R (1990) The effect of intrathecal baclofen on the lower urinary tract in paraplegia. Paraplegia 28:420\u2013427","journal-title":"Paraplegia"},{"key":"1950_CR117","unstructured":"Food and Drug Administration (2011) Highlights of prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5232lbl.pdf. Zugegriffen: 31. Mai 2022"},{"key":"1950_CR118","doi-asserted-by":"crossref","first-page":"834753","DOI":"10.1155\/2011\/834753","volume":"2011","author":"F Van Rey","year":"2011","unstructured":"Van Rey\u00a0F, Heesakkers\u00a0J (2011) Solifenacin in multiple sclerosis patients with overactive bladder: a\u00a0prospective study. Adv Urol 2011:834753","journal-title":"Adv Urol"},{"key":"1950_CR119","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","volume":"367","author":"AG Visco","year":"2012","unstructured":"Visco\u00a0AG, Brubaker\u00a0L, Richter\u00a0HE et\u00a0al (2012) Anticholinergic therapy vs. onabotulinumtoxin A for urgency urinary incontinence. N\u00a0Engl J Med 367:1803\u20131813","journal-title":"N Engl J Med"},{"key":"1950_CR120","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/SPV.0000000000000277","volume":"22","author":"AG Visco","year":"2016","unstructured":"Visco\u00a0AG, Zyczynski\u00a0H, Brubaker\u00a0L et al (2016) Cost-effectiveness analysis of anticholinergics versus botox for urgency urinary incontinence: results from the anticholinergic versus botox comparison randomized trial. Female Pelvic Med Reconstr Surg 22:311\u2013316","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"1950_CR121","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/ageing\/afu017","volume":"43","author":"A Wagg","year":"2014","unstructured":"Wagg\u00a0A, Cardozo\u00a0L, Nitti\u00a0VW et al (2014) The efficacy and tolerability of the \u03b23-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing 43:666\u2013675","journal-title":"Age Ageing"},{"key":"1950_CR122","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s00120-017-0339-y","volume":"56","author":"J Wolfesberger","year":"2017","unstructured":"Wolfesberger\u00a0J, Falkensammer\u00a0CE, Madersbacher\u00a0S (2017) Blasenspeicher- und Entleerungsst\u00f6rungen. Urologe 56:456\u2013464","journal-title":"Urologe"},{"key":"1950_CR123","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/sc.2015.195","volume":"54","author":"J W\u00f6llner","year":"2016","unstructured":"W\u00f6llner\u00a0J, Pannek\u00a0J (2016) Initial experience with the treatment of neurogenic detrusor overactivity with a\u00a0new \u03b2\u20113 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 54:78\u201382","journal-title":"Spinal Cord"},{"key":"1950_CR124","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/sj.sc.3101318","volume":"40","author":"JJ Wyndaele","year":"2002","unstructured":"Wyndaele\u00a0JJ, Van Dromme\u00a0SA (2002) Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40:599\u2013600","journal-title":"Spinal Cord"},{"key":"1950_CR125","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/bju.13068","volume":"116","author":"O Yamaguchi","year":"2015","unstructured":"Yamaguchi\u00a0O, Kakizaki\u00a0H, Homma\u00a0Y et al (2015) Safety and efficacy of mirabegron as \u201eadd-on\u201ctherapy in patients with overactive bladder treated with solifenacin: a\u00a0post-marketing,open-label study in Japan (MILAI study). BJU Int 116:612\u2013622","journal-title":"BJU Int"},{"key":"1950_CR126","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/sc.2014.41","volume":"52","author":"N Yildiz","year":"2014","unstructured":"Yildiz\u00a0N, Akkoc\u00a0Y, Erhan\u00a0B et al (2014) Neurogenic bladder in patients with traumatic spinal cord injury: treatment and follow-up. Spinal Cord 52:462\u2013467","journal-title":"Spinal Cord"},{"key":"1950_CR127","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","volume":"21","author":"TA Zesiewicz","year":"2015","unstructured":"Zesiewicz\u00a0TA, Evatt\u00a0M, Vaughan\u00a0CP et\u00a0al (2015) Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson\u2019s disease. Parkonsonism Relat Disord 21:514\u2013520","journal-title":"Parkonsonism Relat Disord"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01950-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-022-01950-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01950-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T23:51:48Z","timestamp":1674258708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-022-01950-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1007\/s00120-022-01950-0","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"12 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Domurath, R.\u00a0Kirschner-Hermanns, S.\u00a0M\u00f6hr, J.\u00a0Pretzer und I.\u00a0Soljanik geben an, dass kein Interessenkonflikt besteht. J.\u00a0Kutzenberger: Honorierte Vortr\u00e4ge im Auftrag von Farco Pharma nach Publikation der Langfassung der LL. A.\u00a0Angermund: Bezahlte Wissenschaftliche Beratung von Farco Pharma im Zuge der Markteinf\u00fchrung der intravesikalen Instillation von Oxybutynin (Vesoxx<sup>R<\/sup>). Deshalb Enthaltung im Zuge der Abstimmung zum Thema der Oxybutynin-Instillation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}